Semiconductor Metallization and Interconnects
Semiconductor Metallization and Interconnects market is segmented by players, region (country), b ... Read More
Global Personalized Medicine and Epigenomics Market Insights, Forecast to 2028
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Personalized Medicine and Epigenomics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Reagents
1.2.3 Kits
1.2.4 Instruments
1.2.5 Enzymes
1.2.6 Services
1.3 Market by Application
1.3.1 Global Personalized Medicine and Epigenomics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Oncology
1.3.3 Non-Oncology
1.3.4 Cancer Drug Technology
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Personalized Medicine and Epigenomics Market Perspective (2017-2028)
2.2 Personalized Medicine and Epigenomics Growth Trends by Region
2.2.1 Personalized Medicine and Epigenomics Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Personalized Medicine and Epigenomics Historic Market Size by Region (2017-2022)
2.2.3 Personalized Medicine and Epigenomics Forecasted Market Size by Region (2023-2028)
2.3 Personalized Medicine and Epigenomics Market Dynamics
2.3.1 Personalized Medicine and Epigenomics Industry Trends
2.3.2 Personalized Medicine and Epigenomics Market Drivers
2.3.3 Personalized Medicine and Epigenomics Market Challenges
2.3.4 Personalized Medicine and Epigenomics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Personalized Medicine and Epigenomics Players by Revenue
3.1.1 Global Top Personalized Medicine and Epigenomics Players by Revenue (2017-2022)
3.1.2 Global Personalized Medicine and Epigenomics Revenue Market Share by Players (2017-2022)
3.2 Global Personalized Medicine and Epigenomics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Personalized Medicine and Epigenomics Revenue
3.4 Global Personalized Medicine and Epigenomics Market Concentration Ratio
3.4.1 Global Personalized Medicine and Epigenomics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Personalized Medicine and Epigenomics Revenue in 2021
3.5 Personalized Medicine and Epigenomics Key Players Head office and Area Served
3.6 Key Players Personalized Medicine and Epigenomics Product Solution and Service
3.7 Date of Enter into Personalized Medicine and Epigenomics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Personalized Medicine and Epigenomics Breakdown Data by Type
4.1 Global Personalized Medicine and Epigenomics Historic Market Size by Type (2017-2022)
4.2 Global Personalized Medicine and Epigenomics Forecasted Market Size by Type (2023-2028)
5 Personalized Medicine and Epigenomics Breakdown Data by Application
5.1 Global Personalized Medicine and Epigenomics Historic Market Size by Application (2017-2022)
5.2 Global Personalized Medicine and Epigenomics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Personalized Medicine and Epigenomics Market Size (2017-2028)
6.2 North America Personalized Medicine and Epigenomics Market Size by Type
6.2.1 North America Personalized Medicine and Epigenomics Market Size by Type (2017-2022)
6.2.2 North America Personalized Medicine and Epigenomics Market Size by Type (2023-2028)
6.2.3 North America Personalized Medicine and Epigenomics Market Share by Type (2017-2028)
6.3 North America Personalized Medicine and Epigenomics Market Size by Application
6.3.1 North America Personalized Medicine and Epigenomics Market Size by Application (2017-2022)
6.3.2 North America Personalized Medicine and Epigenomics Market Size by Application (2023-2028)
6.3.3 North America Personalized Medicine and Epigenomics Market Share by Application (2017-2028)
6.4 North America Personalized Medicine and Epigenomics Market Size by Country
6.4.1 North America Personalized Medicine and Epigenomics Market Size by Country (2017-2022)
6.4.2 North America Personalized Medicine and Epigenomics Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Personalized Medicine and Epigenomics Market Size (2017-2028)
7.2 Europe Personalized Medicine and Epigenomics Market Size by Type
7.2.1 Europe Personalized Medicine and Epigenomics Market Size by Type (2017-2022)
7.2.2 Europe Personalized Medicine and Epigenomics Market Size by Type (2023-2028)
7.2.3 Europe Personalized Medicine and Epigenomics Market Share by Type (2017-2028)
7.3 Europe Personalized Medicine and Epigenomics Market Size by Application
7.3.1 Europe Personalized Medicine and Epigenomics Market Size by Application (2017-2022)
7.3.2 Europe Personalized Medicine and Epigenomics Market Size by Application (2023-2028)
7.3.3 Europe Personalized Medicine and Epigenomics Market Share by Application (2017-2028)
7.4 Europe Personalized Medicine and Epigenomics Market Size by Country
7.4.1 Europe Personalized Medicine and Epigenomics Market Size by Country (2017-2022)
7.4.2 Europe Personalized Medicine and Epigenomics Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Personalized Medicine and Epigenomics Market Size (2017-2028)
8.2 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Type
8.2.1 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Personalized Medicine and Epigenomics Market Share by Type (2017-2028)
8.3 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Application
8.3.1 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Personalized Medicine and Epigenomics Market Share by Application (2017-2028)
8.4 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Region
8.4.1 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Personalized Medicine and Epigenomics Market Size (2017-2028)
9.2 Latin America Personalized Medicine and Epigenomics Market Size by Type
9.2.1 Latin America Personalized Medicine and Epigenomics Market Size by Type (2017-2022)
9.2.2 Latin America Personalized Medicine and Epigenomics Market Size by Type (2023-2028)
9.2.3 Latin America Personalized Medicine and Epigenomics Market Share by Type (2017-2028)
9.3 Latin America Personalized Medicine and Epigenomics Market Size by Application
9.3.1 Latin America Personalized Medicine and Epigenomics Market Size by Application (2017-2022)
9.3.2 Latin America Personalized Medicine and Epigenomics Market Size by Application (2023-2028)
9.3.3 Latin America Personalized Medicine and Epigenomics Market Share by Application (2017-2028)
9.4 Latin America Personalized Medicine and Epigenomics Market Size by Country
9.4.1 Latin America Personalized Medicine and Epigenomics Market Size by Country (2017-2022)
9.4.2 Latin America Personalized Medicine and Epigenomics Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Personalized Medicine and Epigenomics Market Size (2017-2028)
10.2 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Type
10.2.1 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Personalized Medicine and Epigenomics Market Share by Type (2017-2028)
10.3 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Application
10.3.1 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Personalized Medicine and Epigenomics Market Share by Application (2017-2028)
10.4 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Country
10.4.1 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Details
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Personalized Medicine and Epigenomics Introduction
11.1.4 Abbott Laboratories Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
11.1.5 Abbott Laboratories Recent Developments
11.2 Affymetrix
11.2.1 Affymetrix Company Details
11.2.2 Affymetrix Business Overview
11.2.3 Affymetrix Personalized Medicine and Epigenomics Introduction
11.2.4 Affymetrix Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
11.2.5 Affymetrix Recent Developments
11.3 Agilent Technologies
11.3.1 Agilent Technologies Company Details
11.3.2 Agilent Technologies Business Overview
11.3.3 Agilent Technologies Personalized Medicine and Epigenomics Introduction
11.3.4 Agilent Technologies Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
11.3.5 Agilent Technologies Recent Developments
11.4 Astellas Pharmaceuticals
11.4.1 Astellas Pharmaceuticals Company Details
11.4.2 Astellas Pharmaceuticals Business Overview
11.4.3 Astellas Pharmaceuticals Personalized Medicine and Epigenomics Introduction
11.4.4 Astellas Pharmaceuticals Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
11.4.5 Astellas Pharmaceuticals Recent Developments
11.5 BAYER AG
11.5.1 BAYER AG Company Details
11.5.2 BAYER AG Business Overview
11.5.3 BAYER AG Personalized Medicine and Epigenomics Introduction
11.5.4 BAYER AG Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
11.5.5 BAYER AG Recent Developments
11.6 Bio Vision
11.6.1 Bio Vision Company Details
11.6.2 Bio Vision Business Overview
11.6.3 Bio Vision Personalized Medicine and Epigenomics Introduction
11.6.4 Bio Vision Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
11.6.5 Bio Vision Recent Developments
11.7 Celgene Corp.
11.7.1 Celgene Corp. Company Details
11.7.2 Celgene Corp. Business Overview
11.7.3 Celgene Corp. Personalized Medicine and Epigenomics Introduction
11.7.4 Celgene Corp. Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
11.7.5 Celgene Corp. Recent Developments
11.8 Emd Millipore
11.8.1 Emd Millipore Company Details
11.8.2 Emd Millipore Business Overview
11.8.3 Emd Millipore Personalized Medicine and Epigenomics Introduction
11.8.4 Emd Millipore Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
11.8.5 Emd Millipore Recent Developments
11.9 Epigenomics AG
11.9.1 Epigenomics AG Company Details
11.9.2 Epigenomics AG Business Overview
11.9.3 Epigenomics AG Personalized Medicine and Epigenomics Introduction
11.9.4 Epigenomics AG Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
11.9.5 Epigenomics AG Recent Developments
11.10 Epigentex
11.10.1 Epigentex Company Details
11.10.2 Epigentex Business Overview
11.10.3 Epigentex Personalized Medicine and Epigenomics Introduction
11.10.4 Epigentex Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
11.10.5 Epigentex Recent Developments
11.11 Envivo Pharmaceuticals (Forum Pharmaceutricals)
11.11.1 Envivo Pharmaceuticals (Forum Pharmaceutricals) Company Details
11.11.2 Envivo Pharmaceuticals (Forum Pharmaceutricals) Business Overview
11.11.3 Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Introduction
11.11.4 Envivo Pharmaceuticals (Forum Pharmaceutricals) Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
11.11.5 Envivo Pharmaceuticals (Forum Pharmaceutricals) Recent Developments
11.12 Gilead Sciences
11.12.1 Gilead Sciences Company Details
11.12.2 Gilead Sciences Business Overview
11.12.3 Gilead Sciences Personalized Medicine and Epigenomics Introduction
11.12.4 Gilead Sciences Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
11.12.5 Gilead Sciences Recent Developments
11.13 Glaxosmithkline
11.13.1 Glaxosmithkline Company Details
11.13.2 Glaxosmithkline Business Overview
11.13.3 Glaxosmithkline Personalized Medicine and Epigenomics Introduction
11.13.4 Glaxosmithkline Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
11.13.5 Glaxosmithkline Recent Developments
11.14 Illumina Inc.
11.14.1 Illumina Inc. Company Details
11.14.2 Illumina Inc. Business Overview
11.14.3 Illumina Inc. Personalized Medicine and Epigenomics Introduction
11.14.4 Illumina Inc. Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
11.14.5 Illumina Inc. Recent Developments
11.15 Johnson & Johnson
11.15.1 Johnson & Johnson Company Details
11.15.2 Johnson & Johnson Business Overview
11.15.3 Johnson & Johnson Personalized Medicine and Epigenomics Introduction
11.15.4 Johnson & Johnson Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
11.15.5 Johnson & Johnson Recent Developments
11.16 Karus Therapeutics Limited
11.16.1 Karus Therapeutics Limited Company Details
11.16.2 Karus Therapeutics Limited Business Overview
11.16.3 Karus Therapeutics Limited Personalized Medicine and Epigenomics Introduction
11.16.4 Karus Therapeutics Limited Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
11.16.5 Karus Therapeutics Limited Recent Developments
11.17 Laboratory Corp. Of America Holdings
11.17.1 Laboratory Corp. Of America Holdings Company Details
11.17.2 Laboratory Corp. Of America Holdings Business Overview
11.17.3 Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Introduction
11.17.4 Laboratory Corp. Of America Holdings Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
11.17.5 Laboratory Corp. Of America Holdings Recent Developments
11.18 LES Laboratoires Servier
11.18.1 LES Laboratoires Servier Company Details
11.18.2 LES Laboratoires Servier Business Overview
11.18.3 LES Laboratoires Servier Personalized Medicine and Epigenomics Introduction
11.18.4 LES Laboratoires Servier Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
11.18.5 LES Laboratoires Servier Recent Developments
11.19 Merck
11.19.1 Merck Company Details
11.19.2 Merck Business Overview
11.19.3 Merck Personalized Medicine and Epigenomics Introduction
11.19.4 Merck Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
11.19.5 Merck Recent Developments
11.20 Naturewise Biotech & Medicals Corp.
11.20.1 Naturewise Biotech & Medicals Corp. Company Details
11.20.2 Naturewise Biotech & Medicals Corp. Business Overview
11.20.3 Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Introduction
11.20.4 Naturewise Biotech & Medicals Corp. Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
11.20.5 Naturewise Biotech & Medicals Corp. Recent Developments
11.21 Novartis Pharma AG
11.21.1 Novartis Pharma AG Company Details
11.21.2 Novartis Pharma AG Business Overview
11.21.3 Novartis Pharma AG Personalized Medicine and Epigenomics Introduction
11.21.4 Novartis Pharma AG Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
11.21.5 Novartis Pharma AG Recent Developments
11.22 Oncolys Biopharma Inc.
11.22.1 Oncolys Biopharma Inc. Company Details
11.22.2 Oncolys Biopharma Inc. Business Overview
11.22.3 Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Introduction
11.22.4 Oncolys Biopharma Inc. Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
11.22.5 Oncolys Biopharma Inc. Recent Developments
11.23 Orchid Chemicals & Pharmaceuticals Limited
11.23.1 Orchid Chemicals & Pharmaceuticals Limited Company Details
11.23.2 Orchid Chemicals & Pharmaceuticals Limited Business Overview
11.23.3 Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Introduction
11.23.4 Orchid Chemicals & Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
11.23.5 Orchid Chemicals & Pharmaceuticals Limited Recent Developments
11.24 Progen Pharmaceuticals Limited
11.24.1 Progen Pharmaceuticals Limited Company Details
11.24.2 Progen Pharmaceuticals Limited Business Overview
11.24.3 Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Introduction
11.24.4 Progen Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
11.24.5 Progen Pharmaceuticals Limited Recent Developments
11.25 Quest Diagnostics
11.25.1 Quest Diagnostics Company Details
11.25.2 Quest Diagnostics Business Overview
11.25.3 Quest Diagnostics Personalized Medicine and Epigenomics Introduction
11.25.4 Quest Diagnostics Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
11.25.5 Quest Diagnostics Recent Developments
11.26 Roche Holding AG
11.26.1 Roche Holding AG Company Details
11.26.2 Roche Holding AG Business Overview
11.26.3 Roche Holding AG Personalized Medicine and Epigenomics Introduction
11.26.4 Roche Holding AG Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
11.26.5 Roche Holding AG Recent Developments
11.27 Rubicon Genomics
11.27.1 Rubicon Genomics Company Details
11.27.2 Rubicon Genomics Business Overview
11.27.3 Rubicon Genomics Personalized Medicine and Epigenomics Introduction
11.27.4 Rubicon Genomics Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
11.27.5 Rubicon Genomics Recent Developments
11.28 Takeda Pharmaceutical Company Limited
11.28.1 Takeda Pharmaceutical Company Limited Company Details
11.28.2 Takeda Pharmaceutical Company Limited Business Overview
11.28.3 Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Introduction
11.28.4 Takeda Pharmaceutical Company Limited Revenue in Personalized Medicine and Epigenomics Business (2017-2022)
11.28.5 Takeda Pharmaceutical Company Limited Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Personalized Medicine and Epigenomics Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Reagents
Table 3. Key Players of Kits
Table 4. Key Players of Instruments
Table 5. Key Players of Enzymes
Table 6. Key Players of Services
Table 7. Global Personalized Medicine and Epigenomics Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 8. Global Personalized Medicine and Epigenomics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 9. Global Personalized Medicine and Epigenomics Market Size by Region (2017-2022) & (US$ Million)
Table 10. Global Personalized Medicine and Epigenomics Market Share by Region (2017-2022)
Table 11. Global Personalized Medicine and Epigenomics Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 12. Global Personalized Medicine and Epigenomics Market Share by Region (2023-2028)
Table 13. Personalized Medicine and Epigenomics Market Trends
Table 14. Personalized Medicine and Epigenomics Market Drivers
Table 15. Personalized Medicine and Epigenomics Market Challenges
Table 16. Personalized Medicine and Epigenomics Market Restraints
Table 17. Global Personalized Medicine and Epigenomics Revenue by Players (2017-2022) & (US$ Million)
Table 18. Global Personalized Medicine and Epigenomics Revenue Share by Players (2017-2022)
Table 19. Global Top Personalized Medicine and Epigenomics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Personalized Medicine and Epigenomics as of 2021)
Table 20. Ranking of Global Top Personalized Medicine and Epigenomics Companies by Revenue (US$ Million) in 2021
Table 21. Global 5 Largest Players Market Share by Personalized Medicine and Epigenomics Revenue (CR5 and HHI) & (2017-2022)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Personalized Medicine and Epigenomics Product Solution and Service
Table 24. Date of Enter into Personalized Medicine and Epigenomics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Personalized Medicine and Epigenomics Market Size by Type (2017-2022) & (US$ Million)
Table 27. Global Personalized Medicine and Epigenomics Revenue Market Share by Type (2017-2022)
Table 28. Global Personalized Medicine and Epigenomics Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 29. Global Personalized Medicine and Epigenomics Revenue Market Share by Type (2023-2028)
Table 30. Global Personalized Medicine and Epigenomics Market Size by Application (2017-2022) & (US$ Million)
Table 31. Global Personalized Medicine and Epigenomics Revenue Share by Application (2017-2022)
Table 32. Global Personalized Medicine and Epigenomics Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 33. Global Personalized Medicine and Epigenomics Revenue Share by Application (2023-2028)
Table 34. North America Personalized Medicine and Epigenomics Market Size by Type (2017-2022) & (US$ Million)
Table 35. North America Personalized Medicine and Epigenomics Market Size by Type (2023-2028) & (US$ Million)
Table 36. North America Personalized Medicine and Epigenomics Market Size by Application (2017-2022) & (US$ Million)
Table 37. North America Personalized Medicine and Epigenomics Market Size by Application (2023-2028) & (US$ Million)
Table 38. North America Personalized Medicine and Epigenomics Market Size by Country (2017-2022) & (US$ Million)
Table 39. North America Personalized Medicine and Epigenomics Market Size by Country (2023-2028) & (US$ Million)
Table 40. Europe Personalized Medicine and Epigenomics Market Size by Type (2017-2022) & (US$ Million)
Table 41. Europe Personalized Medicine and Epigenomics Market Size by Type (2023-2028) & (US$ Million)
Table 42. Europe Personalized Medicine and Epigenomics Market Size by Application (2017-2022) & (US$ Million)
Table 43. Europe Personalized Medicine and Epigenomics Market Size by Application (2023-2028) & (US$ Million)
Table 44. Europe Personalized Medicine and Epigenomics Market Size by Country (2017-2022) & (US$ Million)
Table 45. Europe Personalized Medicine and Epigenomics Market Size by Country (2023-2028) & (US$ Million)
Table 46. Asia Pacific Personalized Medicine and Epigenomics Market Size by Type (2017-2022) & (US$ Million)
Table 47. Asia Pacific Personalized Medicine and Epigenomics Market Size by Type (2023-2028) & (US$ Million)
Table 48. Asia Pacific Personalized Medicine and Epigenomics Market Size by Application (2017-2022) & (US$ Million)
Table 49. Asia Pacific Personalized Medicine and Epigenomics Market Size by Application (2023-2028) & (US$ Million)
Table 50. Asia Pacific Personalized Medicine and Epigenomics Market Size by Region (2017-2022) & (US$ Million)
Table 51. Asia Pacific Personalized Medicine and Epigenomics Market Size by Region (2023-2028) & (US$ Million)
Table 52. Latin America Personalized Medicine and Epigenomics Market Size by Type (2017-2022) & (US$ Million)
Table 53. Latin America Personalized Medicine and Epigenomics Market Size by Type (2023-2028) & (US$ Million)
Table 54. Latin America Personalized Medicine and Epigenomics Market Size by Application (2017-2022) & (US$ Million)
Table 55. Latin America Personalized Medicine and Epigenomics Market Size by Application (2023-2028) & (US$ Million)
Table 56. Latin America Personalized Medicine and Epigenomics Market Size by Country (2017-2022) & (US$ Million)
Table 57. Latin America Personalized Medicine and Epigenomics Market Size by Country (2023-2028) & (US$ Million)
Table 58. Middle East and Africa Personalized Medicine and Epigenomics Market Size by Type (2017-2022) & (US$ Million)
Table 59. Middle East and Africa Personalized Medicine and Epigenomics Market Size by Type (2023-2028) & (US$ Million)
Table 60. Middle East and Africa Personalized Medicine and Epigenomics Market Size by Application (2017-2022) & (US$ Million)
Table 61. Middle East and Africa Personalized Medicine and Epigenomics Market Size by Application (2023-2028) & (US$ Million)
Table 62. Middle East and Africa Personalized Medicine and Epigenomics Market Size by Country (2017-2022) & (US$ Million)
Table 63. Middle East and Africa Personalized Medicine and Epigenomics Market Size by Country (2023-2028) & (US$ Million)
Table 64. Abbott Laboratories Company Details
Table 65. Abbott Laboratories Business Overview
Table 66. Abbott Laboratories Personalized Medicine and Epigenomics Product
Table 67. Abbott Laboratories Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 68. Abbott Laboratories Recent Developments
Table 69. Affymetrix Company Details
Table 70. Affymetrix Business Overview
Table 71. Affymetrix Personalized Medicine and Epigenomics Product
Table 72. Affymetrix Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 73. Affymetrix Recent Developments
Table 74. Agilent Technologies Company Details
Table 75. Agilent Technologies Business Overview
Table 76. Agilent Technologies Personalized Medicine and Epigenomics Product
Table 77. Agilent Technologies Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 78. Agilent Technologies Recent Developments
Table 79. Astellas Pharmaceuticals Company Details
Table 80. Astellas Pharmaceuticals Business Overview
Table 81. Astellas Pharmaceuticals Personalized Medicine and Epigenomics Product
Table 82. Astellas Pharmaceuticals Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 83. Astellas Pharmaceuticals Recent Developments
Table 84. BAYER AG Company Details
Table 85. BAYER AG Business Overview
Table 86. BAYER AG Personalized Medicine and Epigenomics Product
Table 87. BAYER AG Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 88. BAYER AG Recent Developments
Table 89. Bio Vision Company Details
Table 90. Bio Vision Business Overview
Table 91. Bio Vision Personalized Medicine and Epigenomics Product
Table 92. Bio Vision Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 93. Bio Vision Recent Developments
Table 94. Celgene Corp. Company Details
Table 95. Celgene Corp. Business Overview
Table 96. Celgene Corp. Personalized Medicine and Epigenomics Product
Table 97. Celgene Corp. Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 98. Celgene Corp. Recent Developments
Table 99. Emd Millipore Company Details
Table 100. Emd Millipore Business Overview
Table 101. Emd Millipore Personalized Medicine and Epigenomics Product
Table 102. Emd Millipore Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 103. Emd Millipore Recent Developments
Table 104. Epigenomics AG Company Details
Table 105. Epigenomics AG Business Overview
Table 106. Epigenomics AG Personalized Medicine and Epigenomics Product
Table 107. Epigenomics AG Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 108. Epigenomics AG Recent Developments
Table 109. Epigentex Company Details
Table 110. Epigentex Business Overview
Table 111. Epigentex Personalized Medicine and Epigenomics Product
Table 112. Epigentex Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 113. Epigentex Recent Developments
Table 114. Envivo Pharmaceuticals (Forum Pharmaceutricals) Company Details
Table 115. Envivo Pharmaceuticals (Forum Pharmaceutricals) Business Overview
Table 116. Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Product
Table 117. Envivo Pharmaceuticals (Forum Pharmaceutricals) Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 118. Envivo Pharmaceuticals (Forum Pharmaceutricals) Recent Developments
Table 119. Gilead Sciences Company Details
Table 120. Gilead Sciences Business Overview
Table 121. Gilead Sciences Personalized Medicine and Epigenomics Product
Table 122. Gilead Sciences Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 123. Gilead Sciences Recent Developments
Table 124. Glaxosmithkline Company Details
Table 125. Glaxosmithkline Business Overview
Table 126. Glaxosmithkline Personalized Medicine and Epigenomics Product
Table 127. Glaxosmithkline Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 128. Glaxosmithkline Recent Developments
Table 129. Illumina Inc. Company Details
Table 130. Illumina Inc. Business Overview
Table 131. Illumina Inc. Personalized Medicine and Epigenomics Product
Table 132. Illumina Inc. Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 133. Illumina Inc. Recent Developments
Table 134. Johnson & Johnson Company Details
Table 135. Johnson & Johnson Business Overview
Table 136. Johnson & Johnson Personalized Medicine and Epigenomics Product
Table 137. Johnson & Johnson Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 138. Johnson & Johnson Recent Developments
Table 139. Karus Therapeutics Limited Company Details
Table 140. Karus Therapeutics Limited Business Overview
Table 141. Karus Therapeutics Limited Personalized Medicine and Epigenomics Product
Table 142. Karus Therapeutics Limited Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 143. Karus Therapeutics Limited Recent Developments
Table 144. Laboratory Corp. Of America Holdings Company Details
Table 145. Laboratory Corp. Of America Holdings Business Overview
Table 146. Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Product
Table 147. Laboratory Corp. Of America Holdings Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 148. Laboratory Corp. Of America Holdings Recent Developments
Table 149. LES Laboratoires Servier Company Details
Table 150. LES Laboratoires Servier Business Overview
Table 151. LES Laboratoires Servier Personalized Medicine and Epigenomics Product
Table 152. LES Laboratoires Servier Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 153. LES Laboratoires Servier Recent Developments
Table 154. Merck Company Details
Table 155. Merck Business Overview
Table 156. Merck Personalized Medicine and Epigenomics Product
Table 157. Merck Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 158. Merck Recent Developments
Table 159. Naturewise Biotech & Medicals Corp. Company Details
Table 160. Naturewise Biotech & Medicals Corp. Business Overview
Table 161. Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Product
Table 162. Naturewise Biotech & Medicals Corp. Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 163. Naturewise Biotech & Medicals Corp. Recent Developments
Table 164. Novartis Pharma AG Company Details
Table 165. Novartis Pharma AG Business Overview
Table 166. Novartis Pharma AG Personalized Medicine and Epigenomics Product
Table 167. Novartis Pharma AG Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 168. Novartis Pharma AG Recent Developments
Table 169. Oncolys Biopharma Inc. Company Details
Table 170. Oncolys Biopharma Inc. Business Overview
Table 171. Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Product
Table 172. Oncolys Biopharma Inc. Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 173. Oncolys Biopharma Inc. Recent Developments
Table 174. Orchid Chemicals & Pharmaceuticals Limited Company Details
Table 175. Orchid Chemicals & Pharmaceuticals Limited Business Overview
Table 176. Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Product
Table 177. Orchid Chemicals & Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 178. Orchid Chemicals & Pharmaceuticals Limited Recent Developments
Table 179. Progen Pharmaceuticals Limited Company Details
Table 180. Progen Pharmaceuticals Limited Business Overview
Table 181. Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Product
Table 182. Progen Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 183. Progen Pharmaceuticals Limited Recent Developments
Table 184. Quest Diagnostics Company Details
Table 185. Quest Diagnostics Business Overview
Table 186. Quest Diagnostics Personalized Medicine and Epigenomics Product
Table 187. Quest Diagnostics Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 188. Quest Diagnostics Recent Developments
Table 189. Roche Holding AG Company Details
Table 190. Roche Holding AG Business Overview
Table 191. Roche Holding AG Personalized Medicine and Epigenomics Product
Table 192. Roche Holding AG Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 193. Roche Holding AG Recent Developments
Table 194. Rubicon Genomics Company Details
Table 195. Rubicon Genomics Business Overview
Table 196. Rubicon Genomics Personalized Medicine and Epigenomics Product
Table 197. Rubicon Genomics Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 198. Rubicon Genomics Recent Developments
Table 199. Takeda Pharmaceutical Company Limited Company Details
Table 200. Takeda Pharmaceutical Company Limited Business Overview
Table 201. Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Product
Table 202. Takeda Pharmaceutical Company Limited Revenue in Personalized Medicine and Epigenomics Business (2017-2022) & (US$ Million)
Table 203. Takeda Pharmaceutical Company Limited Recent Developments
Table 204. Research Programs/Design for This Report
Table 205. Key Data Information from Secondary Sources
Table 206. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Personalized Medicine and Epigenomics Market Share by Type: 2021 VS 2028
Figure 2. Reagents Features
Figure 3. Kits Features
Figure 4. Instruments Features
Figure 5. Enzymes Features
Figure 6. Services Features
Figure 7. Global Personalized Medicine and Epigenomics Market Share by Application: 2021 VS 2028
Figure 8. Oncology Case Studies
Figure 9. Non-Oncology Case Studies
Figure 10. Cancer Drug Technology Case Studies
Figure 11. Personalized Medicine and Epigenomics Report Years Considered
Figure 12. Global Personalized Medicine and Epigenomics Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 13. Global Personalized Medicine and Epigenomics Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global Personalized Medicine and Epigenomics Market Share by Region: 2021 VS 2028
Figure 15. Global Personalized Medicine and Epigenomics Market Share by Players in 2021
Figure 16. Global Top Personalized Medicine and Epigenomics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Personalized Medicine and Epigenomics as of 2021)
Figure 17. The Top 10 and 5 Players Market Share by Personalized Medicine and Epigenomics Revenue in 2021
Figure 18. North America Personalized Medicine and Epigenomics Market Size YoY (2017-2028) & (US$ Million)
Figure 19. North America Personalized Medicine and Epigenomics Market Size Market Share by Type (2017-2028)
Figure 20. North America Personalized Medicine and Epigenomics Market Size Market Share by Application (2017-2028)
Figure 21. North America Personalized Medicine and Epigenomics Market Size Share by Country (2017-2028)
Figure 22. United States Personalized Medicine and Epigenomics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Canada Personalized Medicine and Epigenomics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Europe Personalized Medicine and Epigenomics Market Size YoY (2017-2028) & (US$ Million)
Figure 25. Europe Personalized Medicine and Epigenomics Market Size Market Share by Type (2017-2028)
Figure 26. Europe Personalized Medicine and Epigenomics Market Size Market Share by Application (2017-2028)
Figure 27. Europe Personalized Medicine and Epigenomics Market Size Share by Country (2017-2028)
Figure 28. Germany Personalized Medicine and Epigenomics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. France Personalized Medicine and Epigenomics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. U.K. Personalized Medicine and Epigenomics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Italy Personalized Medicine and Epigenomics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Russia Personalized Medicine and Epigenomics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Nordic Countries Personalized Medicine and Epigenomics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Asia-Pacific Personalized Medicine and Epigenomics Market Size YoY (2017-2028) & (US$ Million)
Figure 35. Asia Pacific Personalized Medicine and Epigenomics Market Size Market Share by Type (2017-2028)
Figure 36. Asia Pacific Personalized Medicine and Epigenomics Market Size Market Share by Application (2017-2028)
Figure 37. Asia Pacific Personalized Medicine and Epigenomics Market Size Share by Region (2017-2028)
Figure 38. China Personalized Medicine and Epigenomics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Japan Personalized Medicine and Epigenomics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. South Korea Personalized Medicine and Epigenomics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Southeast Asia Personalized Medicine and Epigenomics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. India Personalized Medicine and Epigenomics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Australia Personalized Medicine and Epigenomics Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 44. Latin America Personalized Medicine and Epigenomics Market Size YoY (2017-2028) & (US$ Million)
Figure 45. Latin America Personalized Medicine and Epigenomics Market Size Market Share by Type (2017-2028)
Figure 46. Latin America Personalized Medicine and Epigenomics Market Size Market Share by Application (2017-2028)
Figure 47. Latin America Personalized Medicine and Epigenomics Market Size Share by Country (2017-2028)
Figure 48. Mexico Personalized Medicine and Epigenomics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 49. Brazil Personalized Medicine and Epigenomics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 50. Middle East & Africa Personalized Medicine and Epigenomics Market Size YoY (2017-2028) & (US$ Million)
Figure 51. Middle East and Africa Personalized Medicine and Epigenomics Market Size Market Share by Type (2017-2028)
Figure 52. Middle East and Africa Personalized Medicine and Epigenomics Market Size Market Share by Application (2017-2028)
Figure 53. Middle East and Africa Personalized Medicine and Epigenomics Market Size Share by Country (2017-2028)
Figure 54. Turkey Personalized Medicine and Epigenomics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 55. Saudi Arabia Personalized Medicine and Epigenomics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 56. UAE Personalized Medicine and Epigenomics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 57. Abbott Laboratories Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 58. Affymetrix Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 59. Agilent Technologies Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 60. Astellas Pharmaceuticals Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 61. BAYER AG Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 62. Bio Vision Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 63. Celgene Corp. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 64. Emd Millipore Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 65. Epigenomics AG Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 66. Epigentex Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 67. Envivo Pharmaceuticals (Forum Pharmaceutricals) Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 68. Gilead Sciences Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 69. Glaxosmithkline Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 70. Illumina Inc. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 71. Johnson & Johnson Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 72. Karus Therapeutics Limited Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 73. Laboratory Corp. Of America Holdings Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 74. LES Laboratoires Servier Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 75. Merck Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 76. Naturewise Biotech & Medicals Corp. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 77. Novartis Pharma AG Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 78. Oncolys Biopharma Inc. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 79. Orchid Chemicals & Pharmaceuticals Limited Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 80. Progen Pharmaceuticals Limited Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 81. Quest Diagnostics Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 82. Roche Holding AG Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 83. Rubicon Genomics Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 84. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2017-2022)
Figure 85. Bottom-up and Top-down Approaches for This Report
Figure 86. Data Triangulation
Figure 87. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Abbott Laboratories Affymetrix Agilent Technologies Astellas Pharmaceuticals BAYER AG Bio Vision Celgene Corp. Emd Millipore Epigenomics AG Epigentex Envivo Pharmaceuticals (Forum Pharmaceutricals) Gilead Sciences Glaxosmithkline Illumina Inc. Johnson & Johnson Karus Therapeutics Limited Laboratory Corp. Of America Holdings LES Laboratoires Servier Merck Naturewise Biotech & Medicals Corp. Novartis Pharma AG Oncolys Biopharma Inc. Orchid Chemicals & Pharmaceuticals Limited Progen Pharmaceuticals Limited Quest Diagnostics Roche Holding AG Rubicon Genomics Takeda Pharmaceutical Company Limited